

Name of the Issue: Mankind Pharma Limited	
1	<b>Type of Issue</b> Initial Public Offer
2	<b>Issue Size (Rs. Mn)</b> 43263.55*
<i>*Source: Prospectus dated April 28, 2023</i>	
3	<b>Grade of issue along with name of the rating agency</b>
	<b>Name</b> NA
	<b>Grade</b> NA

4	<b>Subscription Level (Number of times)</b> 15.4631*
<i>* excluding Anchor Investor Portion and after removing multiple and duplicate bids</i>	
<i>Source: Minutes for basis of allotment dated May 03, 2023</i>	

5 QIB Holding (as a %age of Outstanding Capital) as disclosed to the stock exchanges	
Particulars	%
(i) On Allotment **	5.28%
(ii) at the end of the 1st Quarter immediately after the listing of the issue (June 30, 2023)	4.18%
(iii) at the end of 1st FY (March 31, 2024)	21.01%
(iv) at the end of 2nd FY (March 31, 2025)	24.40%
(v) at the end of 3rd FY (March 31, 2026) *	Not Available

*\*\*Basis of Allotment (excluding pre-issue QIB holding)*

*\* QIB Holding not disclosed as reporting for relevant period has not been completed.*

6 Financials of the issuer		Rs. In lacs		
Parameters	1st FY (March 31,2024)	2nd FY (March 31,2025)	3rd FY (March 31,2026)*	
Income from operations	10,33,477.46	12,20,744.00	Not Available	
Net Profit/(Loss) for the period	1,94,177.17	2,06,059	Not Available	
Paid-up equity share capital	4,005.88	4,126	Not Available	
Reserves excluding revaluation reserves	9,32,302.93	1,42,913	Not Available	

*\* Financials not available as reporting for the relevant years has not been completed.*

7 Trading Status	
The equity shares of Mankind Pharma Limited are listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") (and together with BSE the "Stock Exchanges")	
The equity shares have not been suspended or delisted.	

Particulars	Status
(i) at the end of 1st FY (March 31, 2024)	Frequently Traded
(ii) at the end of 2nd FY (March 31, 2025)	Frequently Traded
(iii) at the end of 3rd FY (March 31, 2026)*	Not Available

*\* Trading status not disclosed as the relevant fiscal years have not been completed.*

<b>8 Change in Directors of Issuer from the disclosures in the offer document</b>							
Particulars	Name of Director	Appointed / Resigned					
(i) at the end of 1st FY (March 31, 2024)	No change	NA					
(ii) at the end of 2nd FY (March 31, 2025)	No change	NA					
(iii) at the end of 3rd FY (March 31, 2026)*	Not Available	Not Available					
<i>* Changes in Directors of Issuer not updated as the relevant financial years have not been completed</i>							
<b>9 Status of implementation of project/ commencement of commercial production</b>							
(i) as disclosed in the offer document							Not applicable
(ii) Actual implementation							Not applicable
(iii) Reasons for delay in implementation, if any							Not applicable
<b>10 Status of utilization of issue proceeds</b>							
(i) as disclosed in the offer document							Not applicable
(ii) Actual implementation							Not applicable
(iii) Reasons for delay in implementation, if any							Not applicable
<b>11 Comments of monitoring agency, if applicable</b>							
(i) Comments on use of funds							Not applicable
(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document							Not applicable
(iii) Any other reservations expressed by the monitoring agency about the end use of funds							Not applicable
<b>12 Pricing Data</b>							
Designated Stock Exchange	NSE						
Issue Price (Rs.)	1080.00						
Listing Date	May 09, 2023						
Price parameters	At close of listing day- May 09, 2023	Close of 30th calendar day from listing day	Close of 90th calendar day from listing day	As at the end of the 1st FY after the listing of the issue (31st March, 2024)			
				Closing price	High	Low	
Market Price	1,430.00	1,486.2	1,803.5	2,300.8	2,336.4	1,322.7	
Nifty 50*	18,265.95	18,726.4	19,597.3	22,326.9	22,493.6	17,398.1	
Price parameters	As at the end of the 2nd FY after the listing of the issue (31st March, 2025)			As at the end of the 3rd FY after the listing of the issue (31st March, 2026) <sup>(1)</sup>			
	Closing price	High	Low	Closing price	High	Low	
Market Price	2,424.75	3,054.80	1,901.05	Not Available	Not Available	Not Available	
Nifty 50*	23,519.35	26,277.35	21,281.45	Not Available	Not Available	Not Available	

\* Being index of NSE, the designated stock exchange

(1) The pricing data is not disclosed as the relevant fiscal years have not been completed

**13 Basis for Issue Price**

Accounting ratio	Face Value per share (Rs.)	As disclosed in offer document*	At the end of 1st FY (March 31,2024)	At the end of 1st FY (March 31,2025)	At the end of 1st FY (March 31,2026)**	
<b>EPS (Diluted)</b>	<b>Company</b>					
	<i>Consolidated</i>	1	35.78	47.68	49.20	Not Available
	<b>Peer Group:</b>					
	<i>Sun Pharmaceuticals Industries Limited</i>	1	13.60	39.9	17.80	Not Available
	<i>Cipla Limited</i>	2	31.17	51.01	63.82	Not Available
	<i>Zydus Lifesciences Limited</i>	1	43.83	38.14	57.39	Not Available
	<i>Torrent Pharmaceutical Limited</i>	5	22.97	48.94	55.79	Not Available
	<i>Alkem Laboratories</i>	2	137.63	150.19	181.11	Not Available
	<i>JB Chemicals &amp; Pharmaceuticals Limited</i>	2	49.82	34.85	41.16	Not Available
	<i>Eris Lifesciences Limited</i>	1	29.88	28.79	5.68	Not Available
	<i>Ipca Laboratories Limited</i>	2	34.85	21.57	25.65	Not Available
	<i>Abbott India Limited</i>	10	375.86	565.28	665.62	Not Available
	<i>Glaxosmithkline Pharmaceuticals Limited</i>	10	100.04	34.83	—	Not Available
	<i>Dabur India Limited</i>	1	9.81	10.38	9.95	Not Available
	<i>Procter &amp; Gamble Health Limited</i>	10	116.00	Not Available	110.97	Not Available
	<i>Zydus Wellness Limited</i>	10	48.54	41.94	4.81	Not Available
			<b>Industry Avg</b>	<b>78.00</b>	<b>88.82</b>	<b>103.31</b>
<b>P/E</b>	<b>Company</b>					
	<i>Consolidated</i>	1	30.18	48.25	49.00	Not Available
	<b>Peer Group:</b>					
	<i>Sun Pharmaceuticals Industries Limited</i>	1	71.54	40.62	97.41	Not Available
	<i>Cipla Limited</i>	2	28.18	29.35	23.09	Not Available
	<i>Zydus Lifesciences Limited</i>	1	10.95	26.41	17.09	Not Available
	<i>Torrent Pharmaceutical Limited</i>	5	66.25	53.14	58.14	Not Available
	<i>Alkem Laboratories</i>	2	23.03	32.90	26.82	Not Available
	<i>JB Chemicals &amp; Pharmaceuticals Limited</i>	2	39.48	47.36	41.83	Not Available
	<i>Eris Lifesciences Limited</i>	1	19.1	29.29	63.57	Not Available
	<i>Ipca Laboratories Limited</i>	2	22.38	57.37	41.28	Not Available
	<i>Abbott India Limited</i>	10	56.19	47.98	47.34	Not Available
	<i>Glaxosmithkline Pharmaceuticals Limited</i>	10	57.03	55.89	—	Not Available
	<i>Dabur India Limited</i>	1	54.55	50.40	47.77	Not Available
	<i>Procter &amp; Gamble Health Limited</i>	10	42.27	Not Available	120.80	Not Available
	<i>Zydus Wellness Limited</i>	10	31.11	35.18	404.47	Not Available
			<b>Industry Avg</b>	<b>40.16</b>	<b>42.16</b>	<b>82.46</b>

	<b>Company</b>					
	<i>Consolidated</i>	1	23.29%	20.74%	13.70%	Not Available
	<b>Peer Group:</b>					
	<i>Sun Pharmaceuticals Industries Limited</i>	1	6.82%	15.04%	13.09%	Not Available
	<i>Cipla Limited</i>	2	12.08%	15.55%	16.84%	Not Available
	<i>Zydus Lifesciences Limited</i>	1	26.40%	19.46%	27.25%	Not Available
	<i>Torrent Pharmaceutical Limited</i>	5	13.06%	24.15%	24.87%	Not Available
	<i>Alkem Laboratories</i>	2	19.05%	17.57%	18.48%	Not Available
<b>RoNW</b>	<i>JB Chemicals &amp; Pharmaceuticals Limited</i>	2	18.06%	18.90%	19.35%	Not Available
	<i>Eris Lifesciences Limited</i>	1	21.28%	15.35%	3.07%	Not Available
	<i>Ipca Laboratories Limited</i>	2	16.10%	8.36%	8.50%	Not Available
	<i>Abbott India Limited</i>	10	28.32%	32.48%	33.41%	Not Available
	<i>Glaxosmithkline Pharmaceuticals Limited</i>	10	63.64%	33.19%	—	Not Available
	<i>Dabur India Limited</i>	1	20.75%	18.36%	16.11%	Not Available
	<i>Procter &amp; Gamble Health Limited</i>	10	31.23%	Not Available	34.30%	Not Available
	<i>Zydus Wellness Limited</i>	10	6.38%	4.98%	0.76%	Not Available
	<b>Industry Avg</b>		21.78%	18.62%	18%	Not Available
	<b>Company</b>					
	<i>Consolidated</i>	10	31.76	233.73	355.34	Not Available
	<b>Peer Group:</b>					
	<i>Sun Pharmaceuticals Industries Limited</i>	1	200.10	265.35	227.98	Not Available
	<i>Cipla Limited</i>	2	258.32	330.78	193.71	Not Available
	<i>Zydus Lifesciences Limited</i>	1	166.05	197.07	105.95	Not Available
	<i>Torrent Pharmaceutical Limited</i>	5	175.89	202.58	22.40	Not Available
	<i>Alkem Laboratories</i>	2	722.44	862.46	1,002.33	Not Available
<b>NAV per share</b>	<i>JB Chemicals &amp; Pharmaceuticals Limited</i>	2	240.83	188.37	217.46	Not Available
	<i>Eris Lifesciences Limited</i>	1	140.39	190.12	184.64	Not Available
	<i>Ipca Laboratories Limited</i>	2	216.47	249.59	220.50	Not Available
	<i>Abbott India Limited</i>	10	1,327.00	1,740.71	199.21	Not Available
	<i>Glaxosmithkline Pharmaceuticals Limited</i>	10	157.19	104.93	—	Not Available
	<i>Dabur India Limited</i>	1	47.41	55.68	6.09	Not Available
	<i>Procter &amp; Gamble Health Limited</i>	10	371.39	Not Available	21.92	Not Available
	<i>Zydus Wellness Limited</i>	10	761.26	841.95	6,343.71	Not Available
	<b>Industry Avg</b>		368.06	435.80	728.76	Not Available

**Notes**

\* Sourced from Prospectus dated April 28, 2023.

\*\*Not available as the relevant fiscal years have not been completed / information not disclosed

**14 Any other material information**

For further updates and information, please refer stock exchange websites i.e. www.bseindia.com and